Watson Pharmaceuticals
Watson Pharmaceuticals, Incorporated (NYSE: WPI) is the 5th largest pharmaceutical company in the United States based on number of prescriptions dispensed. Based in Corona, California, Watson's Generics division markets over 150 pharmaceutical product families, including one of the largest lines of oral contraceptives in the industry, as well as the generic version of the popular and highly dispensed opiate narcotic pain medication, Vicodin, Hydrocodone Bitartrate/APAP tablets. Watson's Brand division markets over 20 pharmaceutical product families, including Ferrlecit for the treatment of iron deficiency anemia, Rapaflo, for the treatment of benign prostatic hyperplasia, Gelnique, the only gel for the treatment of overactive bladder, Oxytrol, a transdermal matrix patch for the control of overactive bladder, Norco, a popular opioid/narcotic pain medication, Androderm, a transdermal reservoir patch for the treatment of low testosterone, as well as many other brand name medications. In addition, Watson's Distribution division, Anda, markets more than 6,000 pharmaceutical products, making it the 4th largest pharmaceutical distribution company in the United States.
Source: Wikipedia
Campaign Finance
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.
Latest FEC Data
covers through committee's December 31, 2012 filing.-
Summary
overview of the committee's finances- Total Raised:
- $111,532
- Total Spent:
- $112,562
- Cash on Hand:
- $37,383
- Debts:
- $0
Standardized Donation Information
covers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.-
Top Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
-
Republicans vs. Democrats
in dollars. "Other" includes 3rd parties and organizations without official party affiliation. -
State vs. Federal
in dollars -
Top PAC Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
Lobbying
$3,600,000 SpentFigures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Watson Pharmaceuticals
-
Names of Lobbyists
-
Firm Hired Amount Watson Pharmaceuticals $3,600,000 -
Most Frequently Disclosed Lobbying Issues
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Health Issues,
- Telecommunications,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Pharmacy,
- Trade
-
Most Frequently Disclosed Bills
Bill No. Title S.27 Preserve Access to Affordable Generics Act H.R.1249 America Invents Act S.23 Patent Reform Act of 2011 H.R.1065 Pill Mill Crackdown Act of 2011 H.R.1316 Stop Oxy Abuse Act of 2011 H.R.1432 Creating Sunshine, Participation, and Accountability for our Nation Act H.R.1483 Drug Safety Enhancement Act of 2011 S.296 Preserving Access to Life-Saving Medications Act S.316 Fort Hood Victims and Families Benefits Protection Act H.R.1908 To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for oth
Regulations
Mentioned in 19 dockets; Submitted to 3 docketsAll data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Watson Pharmaceuticals" in public comments on proposed federal regulations.
-
Documents Submitted by the Organization
View all submissions data for Watson Pharmaceuticals
Sources:
Regulations.gov
-
Mentions in Document Text
View all mentions data for Watson Pharmaceuticals
Sources:
Regulations.gov
